{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:47:48Z","timestamp":1793245668506,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["ECS00000041"],"award-info":[{"award-number":["ECS00000041"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["1057"],"award-info":[{"award-number":["1057"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["D73C22000840006"],"award-info":[{"award-number":["D73C22000840006"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartrhythmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.hrthm.2024.11.041","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T09:24:14Z","timestamp":1732785854000},"page":"510-525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Managing drug\u2013drug interactions with mavacamten: A focus on combined use of antiarrhythmic drugs and anticoagulants"],"prefix":"10.1016","volume":"22","author":[{"given":"Fabrizio","family":"Ricci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo V.","family":"Molinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Galanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Vagnarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Renda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Gallina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine A.","family":"Luzum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Y.","family":"Khanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar A.","family":"Chahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrthm.2024.11.041_bib1","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","article-title":"Management of hypertrophic cardiomyopathy: JACC State-of-the-Art Review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2024.11.041_bib2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.mayocp.2023.09.009","article-title":"Re-evaluating the incidence and prevalence of clinical hypertrophic cardiomyopathy: an epidemiological study of Olmsted County, Minnesota","volume":"99","author":"Karim","year":"2024","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.hrthm.2024.11.041_bib3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCGEN.122.003832","article-title":"Long-term prevalence of systolic dysfunction in MYBPC3 versus MYH7-related hypertrophic cardiomyopathy","volume":"16","author":"Beltrami","year":"2023","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.hrthm.2024.11.041_bib4","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.jacc.2004.07.045","article-title":"Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy","volume":"44","author":"Van Driest","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2024.11.041_bib5","doi-asserted-by":"crossref","unstructured":"Siontis KC, Geske JB, Ong K, Nishimura RA, Ommen SR, Gersh BJ. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and Mortality in a large high-risk population. J Am Heart Assoc 3:e001002.","DOI":"10.1161\/JAHA.114.001002"},{"key":"10.1016\/j.hrthm.2024.11.041_bib6","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/hc4601.097997","article-title":"Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy","volume":"104","author":"Olivotto","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2024.11.041_bib7","first-page":"e558","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2024.11.041_bib8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0735-1097(01)01727-2","article-title":"Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy","volume":"39","author":"Maron","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2024.11.041_bib9","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2024.11.041_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.15420\/aer.2017:4:2","article-title":"Atrial fibrillation and anticoagulation in hypertrophic cardiomyopathy","volume":"6","author":"Camm","year":"2017","journal-title":"Arrhythm Electrophysiol Rev"},{"key":"10.1016\/j.hrthm.2024.11.041_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euad101","article-title":"Surgical and transcatheter left atrial appendage closure in patients with atrial fibrillation and hypertrophic cardiomyopathy","volume":"25","author":"Khawaja","year":"2023","journal-title":"Europace"},{"key":"10.1016\/j.hrthm.2024.11.041_bib12","first-page":"876","article-title":"From atrial fibrillation management to atrial myopathy assessment: the evolving concept of left atrium disease in hypertrophic cardiomyopathy","volume":"40","author":"Fumagalli","year":"2024","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.hrthm.2024.11.041_bib13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jchf.2017.09.011","article-title":"Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy","volume":"6","author":"Maron","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hrthm.2024.11.041_bib14","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.3390\/jcm12175710","article-title":"Revisiting diagnosis and treatment of hypertrophic cardiomyopathy: current practice and novel perspectives","volume":"12","author":"Ottaviani","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.hrthm.2024.11.041_bib15","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40265-022-01728-w","article-title":"Pharmacological management of hypertrophic cardiomyopathy: from bench to bedside","volume":"82","author":"Palandri","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.hrthm.2024.11.041_bib16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0140-6736(95)91267-3","article-title":"Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy","volume":"346","author":"Sigwart","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.hrthm.2024.11.041_bib17","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacc.2023.05.052","article-title":"First-in-human transapical beating-heart septal myectomy in patients with hypertrophic obstructive cardiomyopathy","volume":"82","author":"Fang","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2024.11.041_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.122.012106","article-title":"Transcatheter myotomy to treat hypertrophic cardiomyopathy and enable transcatheter mitral valve replacement: first-in-human report of septal scoring along the midline endocardium","volume":"15","author":"Greenbaum","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.hrthm.2024.11.041_bib19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamacardio.2022.0259","article-title":"Percutaneous intramyocardial septal radiofrequency ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy","volume":"7","author":"Zhou","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hrthm.2024.11.041_bib20","first-page":"326","article-title":"Transcatheter edge to edge mitral valve repair for mitral regurgitation in hypertrophic cardiomyopathy: a case series","volume":"40","author":"Carasso","year":"2024","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.hrthm.2024.11.041_bib21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/02184923211042136","article-title":"Atrial fibrillation management during septal myectomy for hypertrophic cardiomyopathy: a systematic review","volume":"30","author":"Seco","year":"2022","journal-title":"Asian Cardiovasc Thorac Ann"},{"key":"10.1016\/j.hrthm.2024.11.041_bib22","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","article-title":"Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy","volume":"44","author":"Braunwald","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2024.11.041_bib23","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.hrthm.2024.11.041_bib24","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1093\/eurheartj\/ehad429","article-title":"The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients","volume":"44","author":"DeVries","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2024.11.041_bib26","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hrthm.2024.11.041_bib27","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.hrthm.2024.11.041_bib28","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM Cardiac magnetic resonance substudy analysis","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2024.11.041_bib29","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2024.11.041_bib30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jchf.2023.09.028","article-title":"Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE study, EXPLORER-LTE cohort","volume":"12","author":"Rader","year":"2024","journal-title":"JACC Heart Failure"},{"key":"10.1016\/j.hrthm.2024.11.041_bib31","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hrthm.2024.11.041_bib32","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030607","article-title":"Long-term safety and efficacy of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy: interim results of the PIONEER-OLE study","volume":"13","author":"Masri","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hrthm.2024.11.041_bib33","article-title":"Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"1","author":"Garcia-Pavia","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2024.11.041_bib34","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2024.11.041_bib35","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2024.11.041_bib37","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1021\/ie9015717","article-title":"Physiologically based pharmacokinetics: a simple, all purpose model","volume":"49","author":"Muria","year":"2010","journal-title":"Indust Eng Chem Res"},{"key":"10.1016\/j.hrthm.2024.11.041_bib36","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1389450118666170125144557","article-title":"Cytochrome P450 structure, function and clinical significance: a review","volume":"19","author":"Manikandan","year":"2018","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.hrthm.2024.11.041_bib38","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/cts.12830","article-title":"CYP2C19 allele frequencies in over 2.2 million direct-to-consumer genetics research participants and the potential implication for prescriptions in a large health system","volume":"13","author":"Ionova","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.hrthm.2024.11.041_bib39","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.3390\/jcm9092890","article-title":"Phenoconversion of cytochrome p450 metabolism: a systematic review","volume":"9","author":"Klomp","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.hrthm.2024.11.041_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1201906","article-title":"The impact of CYP2C19 genotype on phenoconversion by concomitant medication","volume":"14","author":"de Jong","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.hrthm.2024.11.041_bib41","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/cpdd.1332","article-title":"Effects of omeprazole and verapamil on the pharmacokinetics, safety, and tolerability of mavacamten: two drug\u2013drug interaction studies in healthy participants","volume":"12","author":"Perera","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.hrthm.2024.11.041_bib42","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/ejhf.541","article-title":"Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives","volume":"18","author":"Ammirati","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hrthm.2024.11.041_bib43","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1161\/CIRCULATIONAHA.118.035455","article-title":"Modernized classification of cardiac antiarrhythmic drugs","volume":"138","author":"Lei","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2024.11.041_bib44","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ijcard.2022.10.014","article-title":"Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: real-world experience in a National Referral Center","volume":"370","author":"Argir\u00f2","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hrthm.2024.11.041_bib45","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2165\/00003088-200645050-00003","article-title":"Clinical pharmacokinetics of ranolazine","volume":"45","author":"Jerling","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.hrthm.2024.11.041_bib46","doi-asserted-by":"crossref","first-page":"617","DOI":"10.12659\/AJCR.893920","article-title":"Amiodarone-induced life-threatening refractory hypotension","volume":"16","author":"Doshi","year":"2015","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.hrthm.2024.11.041_bib47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/24748706.2020.1844926","article-title":"Thirty controversies and considerations in hypertrophic cardiomyopathy","volume":"5","author":"Masri","year":"2021","journal-title":"Structural Heart"},{"key":"10.1016\/j.hrthm.2024.11.041_bib48","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2024.11.041_bib49","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12959-023-00562-8","article-title":"The efficacy and safety of direct oral anticoagulants compared with vitamin K antagonist in patients with hypertrophic cardiomyopathy and atrial fibrillation","volume":"22","author":"Lyu","year":"2024","journal-title":"Thromb J"},{"key":"10.1016\/j.hrthm.2024.11.041_bib50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.15420\/aer.2017.50.1","article-title":"The Significance of drug-drug and drug-food interactions of oral anticoagulation","volume":"7","author":"Vranckx","year":"2018","journal-title":"Arrhythm Electrophysiol Rev"},{"key":"10.1016\/j.hrthm.2024.11.041_bib51","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.vph.2013.07.003","article-title":"The new oral anticoagulants in atrial fibrillation: once daily or twice daily?","volume":"59","author":"Renda","year":"2013","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.hrthm.2024.11.041_bib52","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2147\/DDDT.S368590","article-title":"Review of mavacamten for obstructive hypertrophic cardiomyopathy and future directions","volume":"17","author":"Dong","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.hrthm.2024.11.041_bib53","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/pharmaceutics14061120","article-title":"Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice","volume":"14","author":"Ferri","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.hrthm.2024.11.041_bib54","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.033767","article-title":"Mavacamten for obstructive hypertrophic cardiomyopathy: rationale for clinically guided dose titration to optimize individual response","volume":"13","author":"Owens","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hrthm.2024.11.041_bib55","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2217\/pgs-2021-0158","article-title":"Pharmacogenetics of clopidogrel and warfarin in the treatment of cardiovascular diseases: an overview of reviews","volume":"23","author":"de Lara","year":"2022","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.hrthm.2024.11.041_bib56","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jacbts.2023.12.006","article-title":"Genetics and pharmacogenetics of atrial fibrillation: a mechanistic perspective","volume":"9","author":"Owais","year":"2024","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.hrthm.2024.11.041_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1326776","article-title":"From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice","volume":"15","author":"Shubbar","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.hrthm.2024.11.041_bib58","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Heart Rhythm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527124036257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527124036257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:19:17Z","timestamp":1778818757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547527124036257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1547527124036257"],"URL":"https:\/\/doi.org\/10.1016\/j.hrthm.2024.11.041","relation":{},"ISSN":["1547-5271"],"issn-type":[{"value":"1547-5271","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing drug\u2013drug interactions with mavacamten: A focus on combined use of antiarrhythmic drugs and anticoagulants","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrthm.2024.11.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Heart Rhythm Society.","name":"copyright","label":"Copyright"}]}}